UBS starts Getinge at 'neutral' as growth prospects are priced in

Getinge publ AB

02/09/2026 13:35

** UBS initiates coverage of Swedish medical technology company Getinge GETIb.ST with a "neutral" rating, saying its expected growth improvement is already priced in
** It estimates the company's mix shift towards higher-growth products could result in 12% compound annual growth rate for earnings per share from 2026 to 2030
** Despite meaningful progress on Getinge's historical quality issues, UBS says consensus expectations fully capture its expected growth acceleration and higher margins
** UBS analysis suggests the shares are currently valued as if for a complete quality resolution even as residual matters remain, it says, setting a PT of SEK 255 vs Tuesday's close of SEK 243.2
** Out of 11 analysts that cover the stock, four rate it "strong buy" or "buy", six "hold", and one "sell", according to LSEG data

(Reporting by Marta Frackowiak)
((marta.frackowiak@thomsonreuters.com))